What changed: Rhabdomyosarcoma
Every dated change on the records linked to Rhabdomyosarcoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval2Trial result1Guideline2Milestone6This record1
September 2026 · 1
2024 · 1
2019 · 2
- 2019MilestoneIrinotecan (and liposomal irinotecan)ARST0531: irinotecan does not improve outcome but spares cyclophosphamide
A milestone in how this cancer is treated.
- 2019MilestoneVinorelbineEpSSG RMS 2005: maintenance vinorelbine-cyclophosphamide improves survival (Lancet Oncol)
A milestone in how this cancer is treated.
2016 · 1
2010 · 1
2005 · 2
- 2005GuidelineRhabdomyosarcomaGuideline COG ARST0331 / EpSSG RMS 2005: Low risk (embryonal, favourable site, complete resection)
VA ± reduced cyclophosphamide for 22-24 weeks; radiotherapy for microscopic residual disease.
- 2005GuidelineRhabdomyosarcomaGuideline COG ARST1431; EpSSG RMS 2005: Intermediate risk
VAC (or VAC/VI) 42 weeks with radiotherapy at week 13 (COG); IVA with maintenance vinorelbine-cyclophosphamide 6 months (EpSSG); temsirolimus-VAC/VI per ARST1431 where adopted.